Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been newly diagnosed with a type of acute lymphoblastic leukaemia (ALL) that is either B-cell type or T-cell type, and does not carry a specific genetic marker called the Philadelphia chromosome
- People who are older than 18 years of age at the time of joining the study
- People who are willing and able to sign a form giving their informed consent to participate
Who may not be able to join:
- People whose acute lymphoblastic leukaemia carries the Philadelphia chromosome (a specific genetic change found in some leukaemia cases)
- People whose acute lymphoblastic leukaemia has come back after a previous period of remission or treatment (relapsed ALL)
- People diagnosed with B-cell or T-cell lymphoblastic lymphoma (a related but distinct condition from leukaemia)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: chiara cattaneo, md, Asst Degli Spedali Civili Di Brescia
Phone: 03039951
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of IFI during the early stages of chemotherapy (from onset to TP2, i.e., week 16) in Ph-neg ALL patients
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.